We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Beta-Amyloid Dimers Found in Alzheimer's Patient Brains

By LabMedica International staff writers
Posted on 01 May 2018
The most widely used biomarkers for the early detection of Alzheimer's disease (AD) are currently the concentrations of beta-amyloid (Aβ) and phosphorylated Tau in cerebrospinal fluid. More...
However, it has been observed that not all individuals with alterations in these biomarkers develop the disease.

Molecular exploration into AD had already established a correlation between the concentration of beta-amyloid dimers and the onset of the disease. Nevertheless the nature of these dimers has been hotly debated because it was not known whether the two beta-amyloid molecules that form the dimer were linked by a chemical bond or not.

Spanish and French scientists working with the Institute for Research in Biomedicine (Barcelona, Spain) validated a type of synthetic cross-linked Aβ (CL Aβ) dimers, obtained by means of the photoinduced cross-linking of unmodified proteins (PICUP) reaction, as well-defined mimics of putative brain CL Aβ dimers. They used these PICUP CL Aβ dimers as standards to improve the isolation of brain Aβ dimers and to develop state-of-the-art mass spectrometry (MS) strategies to allow their characterization. They then applied these MS methods to the analysis of brain Aβ dimer samples allowing the detection of the CL [Aβ(6–16)]2 peptide comprising a dityrosine cross-link. These findings were achieved using brain tissue samples from two patients with AD and a control.

The authors concluded that their result demonstrates the presence of CL Aβ dimers in the brains of patients with AD and opens up avenues for establishing new therapeutic targets and developing novel biomarkers for this disease. Aurelio Vázquez de la Torre, PhD, the lead author of study, said, “We have confirmed the potential of these dimers as biomarkers. We have found that the dimers are preserved during the tissue extraction procedure used in the lab and are consequently identical to those in the brains of patients with AD. Furthermore, we have developed a robust and sensitive method that allows us to study the dimers in any biological sample.” The study was published on April 3, 2018, in the journal Analytical Chemistry.

Related Links:
Institute for Research in Biomedicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.